Panelists discuss extended follow-up data from the MonumenTAL-1 trial on talquetamab for relapsed/refractory multiple myeloma, highlighting its sustained efficacy and addressing strategies to manage GPRC5D-related toxicities associated with treatment.
Experts discuss the phase 3 TiNivo-2 study comparing tivozanib plus nivolumab vs tivozanib monotherapy in renal cell carcinoma following prior immune checkpoint inhibitor treatment.
Larysa Sanchez, MD; and Samantha Shenoy, MSN, NP, discuss the management of adverse events with bispecific antibodies like GPRC5D and talquetamab while providing guidance on optimizing treatment outcomes and supportive care, as well as offering advice for managing toxicities and future perspectives on relapsed/refractory multiple myeloma.
